August 26, 2016 10:57 PM ET


Company Overview of Gilead Pharmasset LLC

Company Overview

Gilead Pharmasset LLC, a clinical-stage pharmaceutical company, engages in discovering, developing, and commercializing novel drugs to treat viral infections. The company primarily focuses on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection. Nucleoside/tide analogs are a class of compounds, which act as alternative substrates for the viral polymerase, inhibiting viral replication. The company has three clinical stage product candidates, including PSI-7977, an uracil nucleotide analog polymerase inhibitor, which is initiating a Phase III clinical trials; PSI-938, a guanine nucleotide analog polymerase inhibitor that...

303-A College Road East

Princeton, NJ 08540

United States

Founded in 2004

82 Employees





Key Executives for Gilead Pharmasset LLC

President and Director
Age: 55
Chief Financial Officer and Director
Age: 53
Chief Scientific Officer and Executive Vice President of Pharmaceutical Research
Age: 67
Senior Vice President of Business Development & Scientific Affairs
Age: 53
Vice President of Accounting and Administration
Age: 58
Compensation as of Fiscal Year 2016.

Gilead Pharmasset LLC Key Developments

Cipla to Launch Generic of Gilead Pharma's Hepatitis C Drug Sovald

Cipla has started work on launching generic versions of Gilead pharma's Hepatitis C drug Sovald. Hepcvir is the brand name under which Cipla will be selling the drug in India. The price is yet to be decided. Cipla is one of the several Indian companies which have signed a voluntary licence agreement with Gilead to sell generic versions in the Indian market. The decision comes even as Gilead is yet to receive a patent for the drug in India. It is also locked in dispute with the patent office over protection for an ancillary molecule. Sovaldi (chemical name Sofosbuvir) is considered to be one of the most effective drugs for treating Hep C. The drug created a huge controversy when Gilead announced that it will be pricing the drug at $84,000 in the United States. However, in India and other developing countries, the drug is priced at $900 for 12 weeks treatment.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Gilead Pharmasset LLC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at